An Investigator Initiated Open-label and Explorative Study of Alefacept Treatment for Chronic Extensive Graft Versus Host Disease
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
GVHD response.
6m
No
Michael Y Shapira, MD
Principal Investigator
Department of Stem cell Transplantation & Cancer immunotherapy; Cell Therapy & Transplantation Biology Research Laboratory, Hadassah University Hospital
Israel: Israeli Health Ministry Pharmaceutical Administration
MYS-05-HMO-CTIL
NCT00397332
October 2006
July 2013
Name | Location |
---|